Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine ...

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine ...

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placeboPhase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a…

Opus Genetics Phase 3 Trial for Phentolamine Ophthalmic Solution Meets Primary Endpoint for Night Vision

Opus Genetics announced positive topline results from LYNX-2, a phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Patients who undergo keratorefractive procedures such as Laser-Assisted In Situ Keratomileusis (LASIK), photorefractive keratectomy (PRK), Small-Incision Lenticule Extraction (SMILE) and …

Opus Genetics releases topline results from LYNX-2 evaluating phentolamine ophthalmic solution 0.75%

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced mesopic vision.